6.2.1 Ximelagatran as a Double Prodrug of Melagatran to Increase Permeability
Troy C Sarich (AstraZeneca Plc, USA) presented the discovery and devel- opment of Ximelagatran, which was developed as a double prodrug of melagatran in order to increase permeability while maintaining good pharmacological properties.
Ximelagatran is not charged at intestinal pH and is 170-fold more lipophilic and 80-fold more permeable than its parent drug (Gudmundsson, 2007).
Case study: ximelagatran: a double prodrug of melagatran.
Ximelagatran is prodrug of Exanta and BIBR-1048 is a prodrug of Dabigatran etexilate, an oral anticoagulant drugs developed by AstraZeneca.
واژگان شبکه مترجمین ایران